Novartis' Brolucizumab Shows Dose Advantage Over Eylea In nAMD Trials
Executive Summary
Prospects for Novartis' nAMD eye treatment brolucizumab rose on news the novel anti VEGF treatment met primary and key secondary endpoints in two Phase III studies compared to Eylea, using less dosing.
You may also be interested in...
Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab
Novartis says nAMD eye treatment brolucizumab showed further advantages over Eylea in two Phase III studies, reinforcing plans to file in late 2018 for a commercial launch in 2019.
Regeneron Phase III Stumble Shows RSV Market Is No Child's Play
Failure of Regeneron's anti-RSV antibody suptavumab (REGN2222) comes at a tough time for the company, as some marketed products disappoint and a long-time alliance with Sanofi comes to an end.
Regeneron And Sanofi Antibody Discovery Deal To End
Regeneron and Sanofi have decided to call it a day on their antibody discovery partnership that brought the world Praluent, Dupixent and Kevzara. Regeneron announced that the collaboration was winding down during its Q2 results, where investors were focused on Dupixent's launch progress.